Bio Theus Completed $14 Million Dollars In Series Pre-A Financing, Accelerating Bew Drug Development
Bio Theus has just received around 14 million dollars in Series Pre-A financing. This round of financing was led by Shiyu Capital, and followed by Huaying Investment. The funds will be used to accelerate Bio Theus’s new drug development.
Founded in 2018, Bio Theus is a company specializing in the development of new biopharmaceuticals for the treatment of cancer and metabolic diseases. The company's team has great experience in research and development of new drugs in the biomedical industry and has participated in more than 40 new drug research and development projects.
Bio Theus has a unique antibody development platform that blocks the immune response while blocking the tumor's environment. Bio Theus's drugs have better penetration in solid tumors than existing tumor immunotherapy. The company is currently promoting new biopharmaceutical projects including monoclonal antibodies and multifunctional antibodies.
The company is now working with many companies and research institutions to accelerate the development of new drugs and building new production lines.
About Shiyu Capital
Shiyu Capital is a professional equity investment and asset management institution, focusing on equity investment in the pharmaceutical and healthcare industry, asset allocation and wealth management.
About Huaying Investment
Founded back in 2015, Huaying Investment is a venture capital company in China.